2022年12月23日

Chiratae企業投資WeInnovate Biosolutions作為DeepTech創新者計劃的一部分,這個DeepTech創新者程序由Chiratae企業第六版整合所有種子和早期初創公司的以前的項目重點解決實際,通過跨部門深層技術主要問題。圖片來源:傷風,Chiratae企業,印度領先的風險資本基金今天宣布他們的種子投資WeInnovate Biosolutions,創業工作領域的感染預防和控製作為DeepTech創新者項目六組的一部分。公司已開發出抗菌解決方案,減少院內感染和幫助拯救數百萬住院費用。這一輪的資金將用於產品審批,銷售和市場營銷。DeepTech創新者程序由Chiratae企業第六版整合所有以前的項目的種子和早期初創公司專注於解決實際,通過跨部門深層技術主要問題。超過250 +在水平科技公司是這個計劃的一部分,移動,機器人技術,能源、航空航天、生物技術、生命科學等。這一行動與Chiratae內聯的持續努力回深技術解決方案和提高創新思維來自印度。據世界衛生組織統計,在任何給定的時間全球超過140萬人患有院內感染(HAI)。hai占每年200萬例和80000例死亡。抗菌素耐藥性(AMR)是一種增加全球威脅,與印度最優秀的熱點之一。發表於2015年的一項研究INICC說1 4例在印度是一個海發展的風險。 Any efforts to bring down the antibiotic usage is going to significantly improve the chances to fight antibiotic resistance. The use of antimicrobial medical devices will have a dual effect. It will not only stop the empirical antibiotic usage but also significantly reduce the huge economic burden on a patient’s family incurred due to extended hospitalization stay. This is the first-ever, “Made in India” technology catering to holistic improvement in the Indian Hospitalization scenario. This “completely Indian solution” not only pushes India towards its “Atmanirbhar Bharat” mission but also will lead to a higher attraction for medical tourism. Founded in 2016 by three friends, Dr. Milind Choudhari, Dr. Prasad Bhagat & Dr. Anupama Engineer, Weinnovate Biosolutions is on a mission of ‘Zero Infections’ during a hospital stay. The company aims to achieve this through its range of antimicrobial medical devices that are based on the company’s patented unique, cutting-edge NanoAgCide technology. Their team consists of dedicated scientists and technologists, working together in developing solutions that are rapid and affordable. Their mentors include medical doctors, business strategists, pre-clinical and clinical studies advisors, and product building experts. “With the current steep-rise in hospital-acquired infections (HAI), followed by the indiscriminate use of antibiotics, it was important to come up with a solution that would drastically bring down the incidences of HAI. This would ultimately result in reduced hospitalization stay, improve hospital foot-fall and improve the quality of stay for a patient in any hospital”, said Dr. Milind Choudhari, Founder & CEO of WeInnovate Biosolutions. Speaking on the announcement, Sudhir Sethi, Founder & Chairman, Chiratae Ventures, said “Our goal is to invest in technology solutions across the broad spectrum of deep tech that aim to make people’s lives better. WeInnovate Biosolutions is a unique deep-tech startup that is working to solve a big issue in the healthcare space which is hospital-acquired infections and specifically with the use of catheters, where almost 3.5-4 crore catheters are consumed per year. With their patented technology, WIB has the potential to be a great market leader and capture a significant differentiated market share in India and go global.” Share this article: